INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42301, 3296, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42302, 3297, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42303, 3315, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42304, 17094, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42305, 17137, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42306, 3296, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42307, 3297, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42308, 3315, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42309, 17094, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42310, 17137, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42311, 3296, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42312, 3297, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42313, 3315, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42314, 17094, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42315, 17137, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42316, 3296, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42317, 3297, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42318, 3315, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42319, 17094, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42320, 17137, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42321, 3296, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42322, 3297, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42323, 3315, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42324, 17094, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42325, 17137, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42326, 3296, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42327, 3297, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42328, 3315, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42329, 17094, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42330, 17137, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42331, 3296, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42332, 3297, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42333, 3315, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42334, 17094, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42335, 17137, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42336, 14119, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42337, 17115, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42338, 17116, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42339, 19401, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42340, 19402, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42341, 19403, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42342, 14119, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42343, 17115, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42344, 17116, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42345, 19401, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42346, 19402, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42347, 19403, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42348, 14119, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42349, 17115, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42350, 17116, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42351, 19401, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42352, 19402, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42353, 19403, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42354, 14119, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42355, 17115, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42356, 17116, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42357, 19401, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42358, 19402, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42359, 19403, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42360, 14119, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42361, 17115, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42362, 17116, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42363, 19401, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42364, 19402, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42365, 19403, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42366, 5848, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42367, 5850, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42368, 5852, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42369, 10837, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42370, 19609, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42371, 27431, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42372, 5848, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42373, 5850, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42374, 5852, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42375, 10837, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42376, 19609, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42377, 27431, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42378, 5848, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42379, 5850, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42380, 5852, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42381, 10837, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42382, 19609, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42383, 27431, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42384, 5848, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42385, 5850, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42386, 5852, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42387, 10837, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42388, 19609, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42389, 27431, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42390, 5848, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42391, 5850, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42392, 5852, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42393, 10837, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42394, 19609, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42395, 27431, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42396, 5848, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42397, 5850, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42398, 5852, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42399, 10837, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42400, 19609, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '', 'DDInter', 0);
